Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.
“This randomized study should answer the question of whether CRLX101 can meaningfully impact an area of severely unmet medical need.”
With the 150-patient randomized Phase 2 study in advanced non-small cell lung cancer expected to read out soon, Cerulean is broadening the CRLX101 opportunity in lung cancer.
Starting soon, Cerulean as a good royalty trigger for ARWR.
Why? Cerulean has - for the moment - 5 Programs running. Randomized non small cell lung cancer (NSCLC, data out soon in Q1 2013), ovarian cancer, renal cell cancer (avastin combo), gastric cancer, randomized SCLC with topotecan, and don't forget soon the IND for CRLX301.
I'am sure that the data on the randomized NSCLC are very good, otherwise they wouldn't go forward so fast with the other programs!
The siRNA-platform is licensed from ARWR, as it is CRLX101. ARWR has the rights to get royalties in the range from 10-40%. For Ceruleans CEO, the IPO- environment is encouraging...
They also will get royalties from CLRX-301 (same siRNA-Platform).
ARWR is a RNAi-platform(+)-company, but only since the Roche-deal a year ago. They are moving fast in the clinic. This is not a binary company like Celsion (CLSN). Till july they will have enough cash, but after that, they need CASH from big pharma for a long waited RNAi-partnership. And I a sure they will get at least one - see page 22 on there CP.
Maybe I'am too confident - like the longs on CLSN have been. RNAi has just so much potential. And so - for me - ARWR too. Biotech is not done in one year!
Nno you arenyt too confident. Hiding a toxic chemical an directing payload is never wrong. And ARWRS delivery techs is then validated.
Buy soke ip- tech like Rosetta and your loaded. They are 1000 baggers in the making.